Drtech

Founded in 2000, DRTECH is a Korean digital X-ray imaging solutions company that manufactures and sells both flat-panel digital X-ray detectors and finished imaging systems built around them.

The business is split into a detector segment and a system (finished product) segment, with the system business, which carries a higher average selling price per unit, driving recent top-line growth.

Its core product lineup includes mammography detectors and systems 'RoseM' and 'AIDIA' for breast cancer diagnosis, video detectors for dental and surgical use such as 'EXPEED' and the portable X-ray 'ZeroAlpha', a world-first commercialized industrial bendable detector, and the surgical C-arm system 'EXTRON.' According to the company, overseas sales account for roughly 80% of revenue, reflecting a globally focused business model, and it has maintained a leading share of over 30% in the US indirect-type equine (veterinary) detector market.

More recently, its portable dental X-ray system ZeroAlpha received US FDA clearance, laying groundwork for entry into North America, Europe and Japan, and dental product revenue reportedly grew 28% year over year last year.

Production is carried out at its headquarters plant in Seongnam, Gyeonggi Province, and a plant in Changzhou, Jiangsu Province, China, both of which have undergone capacity expansions.

Subsidiaries include CITECH Medical, related to X-ray systems, and SysBioGen, an early cancer diagnostics biotech affiliate roughly 50%-owned by DRTECH in which CEO Ahn Seong-hyun also serves as co-representative, extending the group's reach beyond imaging into biodiagnostics.

Competitively, DRTECH is a later entrant into a global detector market historically led by US and Japanese players, positioning itself through differentiated technology such as bendable detectors and an integrated detector-system-software total solution strategy.

Consolidated revenue in 2025 came to KRW 116.3 billion, up 19.2% from KRW 97.6 billion in 2024, extending a four-year growth streak from KRW 89.5 billion in 2022.

Profitability, however, worsened: the operating loss widened from KRW 12.1 billion in 2024 to KRW 13.9 billion in 2025, even as the operating margin improved marginally from -12.4% to -11.9%, meaning the absolute loss grew larger.

The net loss attributable to owners also expanded from KRW 19.3 billion in 2024 to KRW 24.0 billion in 2025, marking a fourth straight year of net losses.

Quarterly results, though, show sharp swings: in 2025Q3 the company posted revenue of KRW 34.0 billion, an operating profit of KRW 1.67 billion and a net profit attributable to owners of KRW 2.84 billion, turning profitable, and it did so again in 2026Q2 with revenue of KRW 37.0 billion, operating profit of KRW 1.87 billion and net profit of KRW 2.07 billion.

By contrast, 2025Q4 revenue fell to KRW 23.3 billion alongside a large operating loss of KRW 13.0 billion and a net loss of KRW 16.6 billion, and 2026Q1 saw a smaller loss with revenue of KRW 31.8 billion, an operating loss of KRW 0.6 billion and a net loss of KRW 0.9 billion.

Media reports have attributed the sharp fourth-quarter loss to one-off R&D and inventory-related costs booked under conservative accounting applied during a designated audit process.

Summed across the most recent four quarters (2025Q3-2026Q2), the net loss attributable to owners came to KRW 12.5 billion, as the two profitable quarters were unable to offset the large 2025Q4 loss.

On the balance sheet, the debt ratio fell from 101.8% in 2022 to 93.9% in 2023 before rising again to 146.4% in 2024 and 163.0% in 2025, while operating cash flow swung from a KRW 5.0 billion inflow in 2022 to outflows of KRW 7.9 billion in 2023, KRW 16.0 billion in 2024 and KRW 20.1 billion in 2025, a trend of widening cash outflows for four straight years.

The digital X-ray detector and imaging system market is generally understood to be growing at a moderate pace, supported by rising diagnostic imaging demand from an aging population, expanding mammography screening, the digital conversion of dental imaging, and demand for industrial non-destructive testing (NDT).

The market has historically been led by large US and Japanese players along with European medical device companies, and domestically DRTECH competes with detector makers such as Rayence and Vieworks.

DRTECH is seen as having carved out technical differentiation in niche segments through its integrated detector-system-software total solution strategy, the world-first commercialization of an industrial bendable detector, and a market share above 30% in the US veterinary (equine) segment.

More recently, it became known that DRTECH supplies AI-enabled X-ray products on an ODM basis for a new digital X-ray product Samsung Electronics launched for the first time in eight years, highlighting a collaborative relationship with a major domestic electronics firm.

One corporate analysis report, however, noted that while the bendable detector carries a world-first title as an innovation, it has yet to be fully validated through an expanded revenue contribution or stable profitability improvement.

Intensifying industry competition, currency fluctuations and raw material costs are cited as variables affecting performance, and given that roughly 80% of revenue is derived overseas, changes in medical device certification and procurement policy in key export markets also represent an important variable.

DRTECH stated that a range of products including its 'C-arm' surgical X-ray system, mammography diagnostic system, full-body and general-purpose detectors, and imaging software have obtained EU Medical Device Regulation (CE MDR) certification, which it described as a foundation for strengthening its push into the European market.

Separately, its portable dental X-ray system 'ZeroAlpha' has received US FDA clearance and is preparing entry into North America, Europe and Japan, with the company saying top-tier global dental X-ray makers view ZeroAlpha's performance and design as superior to competing products.

In the mammography segment, the company is developing contrast-enhanced spectral mammography (CESM) technology intended to produce MRI-level imaging via X-ray, and is reportedly preparing a new C-arm surgical video X-ray system.

A company representative noted that the effects of recent investment in domestic and overseas production capacity expansion and R&D staffing have begun to materialize, driving growth through expanded supply of dental video detectors, surgical C-arm systems, mammography diagnostic systems and industrial detectors.

One corporate analysis report noted that the sustainability of future earnings improvement hinges on expanded orders for new products such as the bendable detector and EXTRON, and that improved results could deteriorate again if revenue growth slows or new-product orders disappoint.

The company has decided to consolidate its par value from KRW 100 to KRW 500 per share, with trading suspended from August 20, 2026 and re-listing scheduled for September 10, 2026, a step interpreted as easing burdens associated with its low nominal share price.